

UV Spectrophotometric Method For Estimation Of Telmisartan.

¹Shalini U. Rathod, ² Ankush R. Dudhe, ³ Sonali P.Punde.

¹B.Pharm, ²M.Pharm (Quality Assurance), ³B.Pharm

Ishwar Deshmukh Institute of pharmacy, Digras-445203

Abstract: This article offers an analytical technique for UV Spectrophotometric Telmisartan Validation. The technique made use of UV spectroscopy (Shimadzu, model 1700). The solvent system has a Methanol to water ration of 90:10 at a maximum wave length of 298 nm. System applicability, specificity, precision, linearity, accuracy, interday and intraday assays, robustness, ruggedness, LOD, and LOQ were demonstrated by validation trials. Over the concentration range of 5-45 mg/ml, the technique was linear. The recovery investigations were carried out by adding various amounts (80%, 100%, & 120%) of bulk samples of telmisartan, and the method demonstrated good recoveries (98.04–101.04%). For the determination of telmisartan, the proposed approach was straightforward, sensitive, and reliable with good precision, accuracy, and reproducibility, when calculating the cost.

Keywords: Telmisartan, 0.1 N NaOH, Distilled water, UV- spectrophotometry

Introduction: Chemically, telmisartan is known as 4'[(1,4'-dimethyl-2'propyl[2,6-bi-1 H-benzimidazol]-1'yl]] methyl [1,1'[-biphenyl]-2- carboxylic acid. It is an antihypertensive and angiotensin ll type l blocker. Telmisartan has a lower incidence of cough than ACE inhibitors and is well tolerated in the treatment of mild to severe hypertension. There have been reports on a number of spectrophotometric, chemometric, and chromatographic procedures using a variety of organic solvents, alkalis, acids, and buffers. Following a review of the literature, it has been proposed to create a few straightforward, quick, and precise analytical procedures for estimating. In order to lessen the toxicity, expense, and uncertainty of irritating operations.

Structure of Telmisartan:

International Rezearch Journal

Materials and procedures:

- Chemicals and reagents: Extra-pure methanol and distilled water, telmisartan, and 0.1 N NaOH were used as solvents throughout the experiment. A pharmaceutical preparation was purchased from a nearby pharmacy.
- •Equipment: sonicator, double-beam UV-visible spectrophotometer, and digital balance.

Building a stock solution:

Telmisartan stock solution was created by dissolving 10 mg of each medication in 100 ml of methanol: water (9:1), properly shaking the mixture to ensure complete drug dissolution, and then adjusting the volume with methanol:water (9.1) to get 100 mg/ml

Fig. 1: A typical UV chromatogram showing Telmisartan at 298 nm.




Fig2: linearity graph of Telmisartan




Table1: Linearity table of Telmisartan in methanol: water(90:10).

Sr. No.	Concentr <mark>ation (u</mark> g/ ml)	Absorbance
1.	5	0.326
2.	10	0.548
3.	15	0.835
4.	20	1.082
5.	25	1.334
6.	30	1.551
7.	35	1.791
8.	40	2.056
9.	45	2.349

^{*}Results are the absorbance of nine different drug concentration.

Table 2: Optical characteristics of Telmisartan

Sr. No.	Optical characters*	Values
1.	Absorbance maxima	298 nm
2.	Beers limit	5.45 ug/ ml
3.	% RSD	0.228647
4.	Regression equation (y*)	$0.05 \times + 0.069$
5.	Slope (a)	0.05
6.	Intercept (b)	0.069
7.	Correlation coefficient 0.999	

• Results are the different optical characteristics of the drug.

Making working standard solutions: To make working standard solutions of 5 ppm, 10 ppm, and 45 ppm for Telmisartan's Beers law plot, the prepared stock solution was further diluted with a methanol: water (9:1) ratio. At 298 nm, the absorbance of each solution was measured against a blank of methanol: water (9:1). Telmisartan's typical graph was constructed by placing concentration on the X-axis and absorbance on the Y-axis.

Scanning and determination of maximum wavelength (λmax):

The maximum wavelength (λmax) of the pharmacodynamics agent solutions of specific drug concentrations of 100 mg/ml and 10 mg/ml in methanol: water (9:1) were scanned within the wavelength range of 200-400 nm against a corresponding reagent blank in order to determine the wavelength of maximum absorbance (max). Fig. 1 displayed the resulting spectra. The absorption curves revealed classic Telmisartan absorption peaks at 298 nm.



Table 3: Precision results showing repeatability of Telmisartan

Concentration (ug/ ml)	Absorbance	Calc. Amt.	Statistical analysis
20	1.082	20.26	*Mean-20.28
20	1.078	20.18	
20	1.089	20.4	**St.Dev-0.08
20	1.08	20.22	St.Dev 0.00
20	1.086	20.34	
20	1.083	20.28	***%RSD -
			0.394477

^{*}Results is the mean calculated amount of drug after repeatability study; Results is the standard deviation of the drug after repeatability study; ***Results is the % relative standard deviation of the drug after repeatability study.

Table4: Inter day assay of Telmisartan

Concentration	Absorbance 1	Absorbance 2	Absorbance 3	Statistical
(ug/ ml)				analysis
20	1.084	1.083	1.082	Mean-20.
20	1.089	1.083	1.085	32778
20	1.083	1.089	1.089	urnal
20	1.088	1.088	1.086	Std. Dev0.
20	1.081	1.082	1.086	013878
20	1.092	1.084	1.083	ov P.GP
Mean	1 <mark>.086</mark> 167	1.084833	1 085167	%RSD-
Calc. Amt.	20.34333	20.31667	20.32333	0.06827

^{*}Results are the absorbance of the drug at fixed concentration in first preparation in same day, **Results are the absorbance of the drug at fixed concentration in second preparation in same day; ***Results are the absorbance of the drug fixed concentration in third preparation in same day.

Table 5: Inter day assay of Telmisartan

Sr. No.	Concentration	Day1*	Day2*	Day3*	Statistical
					analysis
1.	20	1.084	1.079	1.082	Mean-20.
2.	20	1.087	1.078	1.085	26111
3.	20	1.083	1.08	1.087	Std. Dev0.
4.	20	1.085	1.08	1.08	038634
5.	20	1.081	1.077	1.081	
6	20	1.08	1.085	1.083	%RSD-
	Mean	1.083333	1.079833	1.083	0.190681
	Calc. Amt.	20.286 <mark>67</mark>	20.21667	20.28	

^{*}Results are the absorbance of drug at fixed concentration in day 1;**Results are the absorbance of drug at fixed concentration in day 2; *** Results are the absorbance of drug at fixed concentration in day 3.

Results and Discussion:

With 0.1 N NaOH and distilled water, the Uv-spectrum of a standard solution of telmisartan was investigated. Spectra showed sharp peaks with well identifiable peaks. All validation parameters displayed values that were within set boundaries. The fact that the recovery percentage was almost 100% shows that the procedure is accurate and reproducible. The suggested method was proven to be straightforward, accurate, and cost-effective; it can be used for standard drug quality control.

Curve of Preparation and Calibration

In Fig. 2, the calibration curve is depicted. It was created by plotting the drug concentration on the x-axis and the absorbance on the y-axis. The drug obeyed Beer's law in the concentration range of 5-45 g/ml, and it was discovered to be linear with a R 2 value of 0.999.

Linearity

Graphics were used to demonstrate how the system fits linearly.

The slope, intercept, and correlation coefficient underwent least square regression analysis. It was discovered that the linearity range fell between 5 and 45 g/ml. Table 1 displays the linearity range, linearity graphs, and table 2 displays the optical features.

Precision

By actually determining eight duplicates of a fixed drug concentration within the range of beer and determining the absorbances using the suggested approach, the precision of the procedure was confirmed.

Standard deviation and percent R.S.D. were computed from this absorbance's mean and are shown in table 3.

Also, the intra- and inter-day variance in the absorption for a group of drug solutions on three distinct days was used to assess the assay's precision. The results of the calculation to determine the intra- and inter-day variation in the absorption of the standard drug solution are shown in tables 3.

Accuracy

Recovery studies were conducted to ascertain the precision of the suggested approach by adding various concentrations (80%, 100%, and 120%) of bulk samples of telmisartan together with an internal standard (I.S) within the linearity range to the preanalyzed formulation of concentration 20 g/ml. Values based on that % recovery were computed. The outcomes were displayed in table 4.

Formulation evaluation

To analyse commercial formulations, two tablets were weighed, crushed, and the powder equivalent to 10 mg of telmisartan was placed into 100 ml volumetric flasks, where it was dissolved in a 9:1 mixture of methanol and water to produce solutions containing 100 g/ml. Once the concentrations were within the linearity range of the individual medications, the solution was sonicated for 15 minutes, filtered, and further diluted with methanol: water (9:1), and the absorbance at 298 nm for the solution against methanol: water was determined (9:1). Here, 10ml was diluted from 3ml. The standard graph was used to estimate the amount of medication in each pill.

Ruggedness: In order to assess ruggedness, a different analyst carried out the same operation, and the outcomes were compared using the same methodology.

Robustness: This process involved varying the ratios of the solvent system's component parts. Results were then contrasted.

LOD and LOQ: The ICH guidelines' equation was used to compute Telmisartan's limit of detection (LOD) and limit of quantification (LOQ).

Sr. No.	Parameters	S. D*	B**	Formula***	Calculation
1.	LOD	0.002515	0.05	3.3(S.D/b)	0.16599
2.	LOQ	0.002515	0.05	10(S.D/b)	0.5030

- *Results are the standard deviation of the drug obtain from the linearity table.
- ** Results are the slope drug obtains from the calibration curve.
- ***Formula for calculation of limit of detection and limit of quantification.

Conclusion:

To estimate the commercial formulation without the interference of excipients or other additives, the suggested approach is straightforward, sensitive, and dependable with good precision and accuracy. As a result, the method can be applied to the regular measurement of Telmisartan. The proposed Uv-spectrophotometric approach is demonstrated to be practical and efficient for the quality control of Telmisartan after comparison to the LOD and LOQ.

Acknowledgement:

Thank you to Prof. Ankush R. Dudhe and Dr. Ranjit DT, principal of Ishwar Deshmukh Institute of Pharmacy in Digras, Yavatmal, Maharashtra, for providing the facilities needed to do this study.

References:

- 1.Practical Pharmaceutical Chemistry, Third Edition, by A. Davidson, CBS Publishers and Distributors, 2007; 265 p.
- 2. The Pharmacological Basis Of Treatments, 2nd Edn, Pergamon Press:1990,1587. Authors: A Rall, A Nies, and G. Goodman.
- 3. B. Matthews, "Regulatory Aspects of Stability Testing in Europe," in T. Carstensen, ed., Marel Dekker Inc., 2008, p. 732.
- 4. Bankey, S., Tapadiya, G., Saboo, S., Bindaiya, D., and Khadbadi, S. International Journal of Chem Tech Research, Vol. 1, 183–188, 2009.
- 5. Blake Pharmaceutical Press: 2002, 841; PS, Martindale, 21st Edn.
- 6. C. Moffat, M. Osselton, and B. Widdop, Clark's Analysis of Drugs and Poisons, Second Edition, Pharmaceutical Press, 2004.
- 7. Principles of Instrumental Analysis, Thomson editors, 2007. Crouch, 276.
- 8. D. Hong and M. Shah developed and validated assays for HPLC stability. Editors in Carstensen T 2008,566. Marel Dekker Inc.
- 9. H. Singh and V. Kapoor, editors, "Medicinal and Pharmaceutical Chemistry, Second Edition," Vallabh Prakashan, 2001, 532.
- 10. Pharmaceutical Press, 2009, p. 210 of JK Singh's Analytical Chemistry, 3rd Edn.

- 11.Fundamentals of Medical Pharmacology, 6th Edition, editors, KD Tripathi 2008,852 Jaypee Brothers Medical Publishers.
- 12. Rajesh PMN, Palled MS, Chatter M, and Bhat AR. Vol. 68, 685–686, Indian Journal of Pharmaceutical Sciences, 2006.
- 13. Palled MS, Chatter M, Rajesh PMN, and Bhat AR, Indian Journal of Pharmaceutical Sciences, vol. 68, 685–686 (2006).
- 14. The Merck Inder, Mary Adele 13th edition, published by Merk Research Lab, Division of Merk and Co., White House Station, NJ, USA, 2001,148. Budhavari S, O'Neil M. J., Smith A, Heckelman P. E. Ed.
- 15. Shah N. J., Suhagia B. H., Shah R. R., and Shah P. B., Development and validation of an HPTLC method for the simultaneous estimation of Telmisartan, Indian J pharm sci. 2007.;69:202-5.
- 16. K.S. Lakshmi, M. Karthick, and V. Amudavalli.
- Telmisartan and hydrochlorothiazide dose formulations in pharmaceuticals are determined using R-HPLC. 2011; 470–476; International Journal of Chemical Sciences, 9(2).
- 17. Sudhakar Nandipati, T.Ravindranadh Reddy, and V. Krishna Reddy. RP-HPLC technique development and validation for telmisartan quantification in tablet and bulk dose forms. International Research Journal of Pharmaceutical and Applied Sciences, 2012, 2(3), 39–43.
- 18. Simultaneous estimation of telmisartan and amlodipine besylate in pharmaceutical dosage form by RP-HLC. Paul Richards M, Bharat kumar D, Mohammad Y, Karunakar Reddy and Siddhartha B.2011;1(2):105–109 in the International Journal of Pharmacy.
- 19. Nivedita G., Hasan Amrohi S., Prashanth Kumar K., Pradeep Kumar T., and Akiful Haque M. IOSRJPBS, 2012, 1(4), 20–23. Simultaneous estimation of atenolol and chlorthalidone as bulk and in tablet dosage form.
- 20. Anonymous. The Pharmaceutical Press, a division of the Royal Pharmaceutical Society of Great Britain, London, 2004,796 and 1601.
- 21. Anonymous, The Extra Pharmacopoeia, 30th Edition, Pharmaceutical Press, London, 1993, 813-1.
- 22.Principles & Practice of Pharmaceuticals, 12th Edition, The Pharmaceutical Press, London, 2009, 802; 22. Anonymous.
- 23. The British Pharmacopeia, Volume I, Volume II, and Volume IV, International Edition, Office of the British Pharmacopeia Commission, London 2009, by Anonymous
- 24. The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 14th Edition, Merck Research Laboratories, a division of Merck and Co. Inc., NJ, USA, 2006, pp. 2193 and 9129.

- 25. The United States Pharmacopeia, 25. Anonymous. 2009, 2246, The United States Pharmacopoeial Convention, Inc., Rockville, Maryland, USA.
- 26.Saboo S.S., Bankey S., Bindaiya S., Deepti Jain, and Khadbadi S.S. Ramipril, hydrochlorthizide, and telmisartan were simultaneously determined by spectrophotometry in Int.J.ChemTech Res., 2009, 1(2), 183–188.
- 27. Bikshal and Madhu Babu Kasimala are number 27.
- Development and validation of a reverse phase-HPLC technique for the simultaneous quantification of chlorthalidone and medoximil in pharmaceutical dosage forms, jamonline, 2012, 2(1), 117-126.
- 28. Development and validation of Spectrophotometric methods for simultaneous estimation of metoprolol succinate and telmisartan in combined pharmaceutical formulation, IJPSR, 2012, 3(5), 1348-1354. Mayur Modi, Rikin Shah, and Mashru R.C.
- 29. Vogel's text book of quantitative chemical analysis, 5th Edition, Mendham J., Denny R.C., Jeffery G.H., and Thomas, Longman Publishers, UK, 1994, p. 10–11.
- 30. Sahasrabudhe, Garole D.J., Mhaske A.A., and Mhaske R.A. Simultaneous determination using RP-HPLC.
- 31. "RP-HPLC method for Simultaneous determination of atorvastatin calcium Telmisartan, medoxomil, Candesartan, Hydrochlorothiazide and chlorthalidone application to commercially Available drug products," IJPSR, 3(3),793-801 (2012).
- 32. Nada.S.Abdelwahab, Determination of atenolol, chlorthalidone and heir degradation Product by TLC-densitometric and chemometric method with application of model Updating, Anal.Methods, 2010, 2,1994-2001.
- 33. Anuraha N. Chivate, Jagadish K. Saboji, Siddharth M. Patil, and Niranjan D. Chivate. J. Pharm. Res., 2012, 5(6), 3331-3333. Development of UV spectrophotometric method for estimation and validation of Telmisartan as a pure API.
- 34. Rajesh PMN, Palled MS, Chatter M, and Bhat AR. Indian Journal of Pharmaceutical Sciences, 2006, 68(5), 685–686, Differential Spectrophotometric Determination of Telmisartan in Tablet Dosage Forms.
- 35.Patil U.P. Simultaneous determination of atorvastatin calcium and telmisartan in tablet dosage form by spectrophotometry, Int.J. ChemTech Res., 2009, 1(4), 970-973. Gandhi S.V., Sengar M.R., and Rajmane V.S.
- 36.Popt B. Mohite, Ramdas b. Pandhara, and Vaidhun H. Bhaskar are the other Eurasian Journal of Analytical Chemistry, 2010, 51(1), 89–94, "Simultaneous Determination of Ramipril and Telmisartan in Tablet Dosage Form by Spectrophotometry."
- 37. Swati U. Kalure, Manish A. Raskar, and Reshma B. Kulkarni. Der Pharma Chemica, 2012, 4(2), 72-730. Simultaneous spectrophotometric estimation of amlodipine besylate and telmisartan in Tablet dosage form.
- 38. Ramesh L. Sawant, Sameer Pawar, and Manish A. Raihan Ahemed. Validated

- 39.Der Pharma chemica, 2012, 4(2), 633-638. Spectrophotometric methods for simultaneous estimation of telmisartan and indapamide in pharmaceutical dosage form.
- 40. Amish A Dangi, Vasant Khasia, Ridhdhi S Sinojiya, and Bhaven J Patel. The simultaneous determination of telmisartan, amlodipine besylate, and hydrochlorthiazide in tablet dosage form was developed and validated using RP-HPLC techniques, according to J.Pharm.Res., 5(8), 4154–4157 (2012).
- 41. Robert D. Braun, Introduction to Instrumental Analysis, Hyderabad: Pharma Book Syndicate, 2006, p. 136.
- 42.Development of UV-Spectrophotometric technique of telmisartan in Tablet formulation, Sagar Tatane, JAPHR, 2011, (1), 23–26.
- 43. Santaji Nalwade, Vangala Ranga Reddy, Inabathina Koteswara Rao, and Dantu Durga Rao. Using stability-indicating ultra Performance liquid chromatography, telmisartan, amlodipine besylate, and hydrochlorothiazide were quickly and simultaneously determined in a combination polypill dosage form.
- 44.Santosh V. Gandhi, Padmanabh B. Deshpande, Varun Godbole, Pankaj Jagdale, Sachin Khiste, and Sayali Kadukar are the 44th and 45th individuals. Using a validated reverse phase HPLC technique, telmisartan and ramipril in tablet dosage form can be determined simultaneously. 2011, 1(2), 283-288. J. Chem. Bio. Phy. Sci.
- 45.HPTLC Quantitative Analysis of Pharmaceutical Formulations, 1st Edition, CBS Publishers and Distributors, New Delhi, 1996, 3–62. Sethi, P.D.
- 46.Instrumental Methods of Chemical Analysis, 25th edition, Goel Publishing House, Meerut, 2006, S 68–S 192. Sharma, B. K.
- 47. Ravindranath Reddy, Krishna Reddy V, and Subhakar Nandipati. Int. Res. J. Pharm. App. Sci., 2012, 2(3), 39–
- 43. Development and Validation of RP-HPLC Method for Estimation of Telmisartan in Bulk and Tablet Dosage Form.
- 48. Sunil Jawla, Kumar Y, Krishnamurthy T, and Jayalakshmi K. Int.J.ChemTech Res., 2010, 2(2), 1625–1633. Development and Validation of Simultaneous HPLC Method for Estimation of Telmisartan and Ramipril in Pharmaceutical Formulation.
- 49. Hanas Bin Hashim, Jayalakshmi B, Ramesh J, and Vijayamirtharaj R. Pharmacie Globale (IJCP), 2010, 4(3), 1-
- 4. Development and validation of RP HPLC method for the simultaneous estimation of telmisartan and atorvastatin calcium in tablet dosage forms.
- 50. Vijay Kumar G, Sambasiva Rao KRS, and Murthy TEGK. IJRPC, 2011, 1(3), 703–706; Validated RP-HPLC Procedure for the quantification of telmisartan in serum samples.